SEC Company Response from Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — May 19, 2017
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: May 19, 2017 · CIK: 0001534120 · Accession: 0001628280-17-005738
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-37590
Letter
Document
Madison A. Jones
+1 202 728 7087
madison.jones@cooley.com
May 19, 2017
Via EDGAR and Electronic Mail
Mr. Jeffrey Gabor
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Cerecor Inc. Preliminary Proxy Statement on Schedule 14A Filed May 12, 2017 File No. 001-37590
Ladies and Gentlemen:
On behalf of Cerecor Inc. (the “Company”), this letter is being transmitted in response to a comment received from the staff (the “Staff”) of the Securities and Exchange Commission, by telephone on May 19, 2017 (the “Comment”), regarding the Company’s Preliminary Proxy Statement on Schedule 14A, filed on May 12, 2017 (the “Proxy Statement”). The text of the Staff’s comment has been included in this letter in italics for your convenience.
Proposal 5: Approval of the Authorized Share Reduction Proposal
1.
Please revise the disclosure in the preliminary proxy statement to discuss any other plans, agreements, arrangements or understandings with regard to the increase of authorized shares as a result of the planned reverse stock split.
Response:
The Company acknowledges the Staff’s comment and has revised the disclosure to page 23 of the Proxy Statement.
***
Mr. Jeffrey Gabor
May 19, 2017
Page Two
Please contact me at (202) 728-7087 with any questions or further comments regarding the Company’s response to the Comment Letter.
Sincerely,
/s/ Madison A. Jones
Show Raw Text
CORRESP
1
filename1.htm
Document
Madison A. Jones
+1 202 728 7087
madison.jones@cooley.com
May 19, 2017
Via EDGAR and Electronic Mail
Mr. Jeffrey Gabor
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Cerecor Inc.
Preliminary Proxy Statement on Schedule 14A
Filed May 12, 2017
File No. 001-37590
Ladies and Gentlemen:
On behalf of Cerecor Inc. (the “Company”), this letter is being transmitted in response to a comment received from the staff (the “Staff”) of the Securities and Exchange Commission, by telephone on May 19, 2017 (the “Comment”), regarding the Company’s Preliminary Proxy Statement on Schedule 14A, filed on May 12, 2017 (the “Proxy Statement”). The text of the Staff’s comment has been included in this letter in italics for your convenience.
Proposal 5: Approval of the Authorized Share Reduction Proposal
1.
Please revise the disclosure in the preliminary proxy statement to discuss any other plans, agreements, arrangements or understandings with regard to the increase of authorized shares as a result of the planned reverse stock split.
Response:
The Company acknowledges the Staff’s comment and has revised the disclosure to page 23 of the Proxy Statement.
***
Mr. Jeffrey Gabor
May 19, 2017
Page Two
Please contact me at (202) 728-7087 with any questions or further comments regarding the Company’s response to the Comment Letter.
Sincerely,
/s/ Madison A. Jones
Madison A. Jones
cc:
Uli Hacksell, Cerecor Inc.
Mariam Morris, Cerecor Inc.
Brent B. Siler, Cooley LLP
145833740 v1